8-K: Inspire Veterinary Partners Delisted from Nasdaq, Moves to OTCQB

Inspire Veterinary Partners, Inc. announced its Class A common stock was delisted from Nasdaq and began trading on the OTCQB Venture Market under the symbol IVPR.

Summary

• Inspire Veterinary Partners, Inc. (the Company) received a notice on November 13, 2025, from Nasdaq regarding non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
• The Company's request to continue its listing on Nasdaq was denied by Nasdaq's Hearings Panel on January 20, 2026.
• The Common Stock was suspended from trading on The Nasdaq Capital Market at the open of trading on January 21, 2026, and will be delisted.
• The Company's Common Stock received approval to trade on the OTCQB Venture Market under the trading symbol IVPR and commenced trading on January 21, 2026.
• Management expressed confidence that the move to OTCQB is a positive change, allowing additional focus on business operations.
• The Company intends to continue its growth of existing locations in 2026 and prepare for the launch of its online pet pharmacy in the first half of the year.
• The Company will continue to file periodic and current reports with the U.S. Securities and Exchange Commission.

Sentiment

Score: 3

Explanation: The delisting from Nasdaq is a significant negative event, indicating a failure to meet listing standards and potentially impacting investor confidence and liquidity. While management attempts to frame the move to OTCQB positively and outlines future growth plans, the underlying reason for delisting is concerning.

Positives

• The Company's Common Stock has secured approval and commenced trading on the OTCQB Venture Market, ensuring continued public trading.
• Management is focused on efficiency, unit-level operations, and continued margin improvement in 2026.
• The Company plans for continued growth of existing locations in 2026.
• A new online pet pharmacy is slated for launch in the first half of 2026, potentially expanding revenue streams.

Negatives

• The Company failed to maintain the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2).
• Nasdaq's Hearings Panel denied the Company's appeal to continue its listing.
• The Common Stock was suspended from trading and will be delisted from The Nasdaq Capital Market, moving to a less liquid and prestigious market.

Risks

• Limited operating history and history of losses.
• Ability to continue operating as a going concern.
• Ability to raise additional capital.
• Ability to complete additional acquisitions.
• Ability to recruit and retain skilled veterinarians.
• Ability to retain existing customers and add new customers.
• The continued growth of the market in which the Company operates.
• Ability to manage growth effectively over the long-term to maintain a high level of service.
• Price volatility of the Class A common stock.
• Impact of geopolitical conflicts, inflation, and macroeconomic instability on the business, broader economy, and ability to forecast future financial performance.

Future Outlook

The Company intends to continue its growth of existing locations in 2026 and plans for the launch of its online pet pharmacy in the first half of the year. Management is focused on efficiency, unit-level operations, and continued margin improvement in 2026.

Management Comments

• "Inspire continues to execute its business strategy and we believe this move to the OTCQB Venture Market is right for us."
• "After accomplishing so much that we're proud of in 2025, we're focused on efficiency, unit level operations and continued margin improvement in 2026."
• "As it provides us additional ability to focus on our business, we are confident the move to the OTCQB is a positive change for Inspire."

Industry Context

The pet healthcare services industry continues to see growth, with companies like Inspire Veterinary Partners aiming to capitalize on this trend. However, the move from Nasdaq to OTCQB may impact investor perception and access to capital compared to peers listed on major exchanges, potentially affecting its competitive positioning.

Stakeholder Impact

• Shareholders: Will experience reduced liquidity and potentially lower trading volume as the stock moves from Nasdaq to the OTCQB Venture Market. The delisting may also negatively impact investor perception and the stock's valuation.
• Management/Employees: The company's focus on efficiency and margin improvement could imply operational adjustments, but the overall business strategy remains focused on growth.

Next Steps

• Nasdaq will file a Form 25 with the U.S. Securities and Exchange Commission to remove the Company's securities from listing and registration.
• The Company intends to continue to file periodic and current reports with the SEC.
• Continued growth of existing locations in 2026.
• Launch of an online pet pharmacy in the first half of 2026.

Key Dates

Recommendation

The delisting from Nasdaq due to failure to meet minimum bid price requirements is a significant negative indicator. While the company has secured trading on the OTCQB, this market typically offers lower liquidity and less investor visibility, which can depress share price. The move suggests underlying financial or operational challenges that led to the non-compliance. Despite management's positive spin and future plans, the immediate impact on shareholder value and the increased risk profile warrant a 'sell' recommendation for investors seeking exposure to more stable, exchange-listed companies.

Keywords

Inspire Veterinary Partners, IVP, IVPR, Nasdaq delisting, OTCQB Venture Market, pet healthcare services, veterinary, online pet pharmacy, SEC filing, 8-K